1996
DOI: 10.1056/nejm199606273342603
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein

Abstract: In patients with septic shock, treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

10
509
3
22

Year Published

1998
1998
2011
2011

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 1,120 publications
(544 citation statements)
references
References 46 publications
10
509
3
22
Order By: Relevance
“…As a result, blocking TNF-␣ is protective in mouse models of TSS with D-galN sensitization. Administration of anti-TNF-␣ has not been protective in bacterial shock including that caused by S. aureus in humans 38 and in mouse models of S. aureus sepsis, 63 possibly because other cytokines also have an important role. For example, it was observed that the systemic levels of the relatively new cytokine IL-17 was profoundly elevated in HLA-DR3 transgenic mice with SAg-induced TSS.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…As a result, blocking TNF-␣ is protective in mouse models of TSS with D-galN sensitization. Administration of anti-TNF-␣ has not been protective in bacterial shock including that caused by S. aureus in humans 38 and in mouse models of S. aureus sepsis, 63 possibly because other cytokines also have an important role. For example, it was observed that the systemic levels of the relatively new cytokine IL-17 was profoundly elevated in HLA-DR3 transgenic mice with SAg-induced TSS.…”
Section: Discussionmentioning
confidence: 99%
“…37 However, TNF-␣ blockade is ineffective or even counterproductive in S. aureus-induced sepsis in humans. 38 These discrepancies warrant an animal model that better recapitulates the disease in humans.…”
mentioning
confidence: 99%
“…Despite promising results of antiinflammatory interventions in animal models (4 -6) and human phase I and II trials (7,8), phase III clinical trials generally failed to show any success (9 -11) and in some cases even appeared detrimental (12). It has been postulated that the immune response in sepsis represents the interplay of two contrasting phenomena related to the inflammatory status of the septic patient.…”
mentioning
confidence: 99%
“…In a study of the efficacy of etanercept in 141 patients with septic shock, there were 10 deaths among 33 patients in the placebo group (30% mortality), 9 deaths among 30 patients receiving lowdose etanercept (0.15 mg/kg body weight) (30% mortality), 14 deaths among 29 patients receiving intermediatedose etanercept (0.45 mg/kg body weight) (48% mortality), and 26 deaths among 49 patients receiving high-dose etanercept (1.5 mg/kg body weight) (53% mortality) (19). There were more gram-positive infectious causes of sepsis in the 3 etanercept groups compared with the placebo group, in addition to an increase in Pseudomonas aeruginosa infection in the group receiving 0.45 mg/kg of etanercept (P ϭ 0.08).…”
Section: Tnf␣ Inhibition and Sepsismentioning
confidence: 99%